Dermira Inc (DERM) Receives $15.10 Consensus Price Target from Brokerages

Shares of Dermira Inc (NASDAQ:DERM) have earned an average rating of “Hold” from the eleven analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $15.10.

DERM has been the topic of several research analyst reports. Guggenheim reissued a “buy” rating and set a $20.00 target price on shares of Dermira in a research note on Tuesday, November 20th. BidaskClub cut Dermira from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 15th. Cantor Fitzgerald set a $20.00 target price on Dermira and gave the company a “buy” rating in a research note on Friday, December 28th. ValuEngine cut Dermira from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research raised Dermira from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a research note on Thursday, January 10th.

A number of hedge funds have recently modified their holdings of the stock. Bank of America Corp DE grew its stake in Dermira by 469.9% in the fourth quarter. Bank of America Corp DE now owns 2,172,328 shares of the biopharmaceutical company’s stock worth $15,619,000 after purchasing an additional 1,791,178 shares during the period. Dimensional Fund Advisors LP grew its stake in Dermira by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 943,421 shares of the biopharmaceutical company’s stock worth $6,783,000 after purchasing an additional 22,816 shares during the period. Sofinnova Investments Inc. grew its stake in Dermira by 9.5% in the fourth quarter. Sofinnova Investments Inc. now owns 542,224 shares of the biopharmaceutical company’s stock worth $3,899,000 after purchasing an additional 46,931 shares during the period. Sofinnova Ventures Inc boosted its holdings in Dermira by 35.9% in the third quarter. Sofinnova Ventures Inc now owns 495,293 shares of the biopharmaceutical company’s stock worth $5,399,000 after acquiring an additional 130,953 shares in the last quarter. Finally, First Midwest Bank Trust Division boosted its holdings in Dermira by 31.2% in the fourth quarter. First Midwest Bank Trust Division now owns 443,625 shares of the biopharmaceutical company’s stock worth $3,190,000 after acquiring an additional 105,565 shares in the last quarter. 87.81% of the stock is currently owned by institutional investors.

DERM stock traded down $0.68 during midday trading on Friday, hitting $6.91. The company had a trading volume of 1,363,360 shares, compared to its average volume of 817,472. The company has a debt-to-equity ratio of 5.21, a quick ratio of 8.48 and a current ratio of 8.70. Dermira has a 52 week low of $6.00 and a 52 week high of $13.84. The company has a market capitalization of $322.64 million, a P/E ratio of -1.32 and a beta of 1.34.

Dermira (NASDAQ:DERM) last posted its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.75) by $0.05. Dermira had a negative return on equity of 309.23% and a negative net margin of 523.25%. As a group, equities analysts predict that Dermira will post -5.69 earnings per share for the current year.

About Dermira

Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.

See Also: What is a Stop Order?

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit